Immunogenicity and safety of a novel MMR vaccine (live, freeze-dried) containing the Edmonston-Zagreb measles strain, the Hoshino mumps strain, and the RA 27/3 rubella strain: Results of a randomized, comparative, active controlled phase III clinical trial

This phase III clinical trial was conducted to evaluate the immunogenicity and safety of the single-dose and multi-dose formulations of a novel MMR vaccine (live, freeze-dried) developed by M/s Cadila Healthcare Limited, India (Cadila MMR vaccine), containing the Hoshino mumps strain, compared to th...

Descripció completa

Dades bibliogràfiques

Autors principals:	Ashwani Sood, Monjori Mitra, Himanshu Arvind Joshi, Uma Siddhartha Nayak, Prashanth Siddaiah, T. Ramesh Babu, Samarendra Mahapatro, Jayesh Sanmukhani, Gaurav Gupta, Ravindra Mittal, Reinhard Glueck
Format:	Artigo
Idioma:	Inglês
Publicat:	Taylor & Francis Group 2017-07-01
Col·lecció:	Human Vaccines & Immunotherapeutics
Matèries:	cadila healthcare limited hoshino mumps strain novel vaccine immunogenicity mmr vaccine measles mumps rubella serum institute of india limited
Accés en línia:	http://dx.doi.org/10.1080/21645515.2017.1302629
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!